Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Neisseria meningitidis serogroup b fhbp fusion protein antigen
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
Neisseria meningitidis serogroup b fhbp fusion protein antigen is a recombinant fusion protein, specifically Factor H binding protein (fHbp), derived from *Neisseria meningitidis* serogroup B. It is produced in *Escherichia coli* cells using recombinant DNA technology and is often adsorbed onto aluminum hydroxide to enhance the immune response. fHbp is a surface-exposed lipoprotein that binds human factor H, a key regulator of the alternative complement pathway, which helps the bacteria evade the host immune system. As a vaccine antigen, it stimulates the body's immune system to produce antibodies that can block factor H binding and activate complement-mediated killing of *N. meningitidis* serogroup B, thereby preventing invasive meningococcal disease. This antigen is a key component of licensed meningococcal serogroup B vaccines such as Bexsero and Trumenba.
- Other names
- Factor H binding proteinfHbprecombinant Neisseria meningitidis group B fHbp fusion protein
02
Targets
CFH (Complement factor H)fHbp (Factor H-binding protein)
Beyond the preview
Go deeper on Neisseria meningitidis serogroup b fhbp fusion protein antigen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Neisseria meningitidis serogroup b fhbp fusion protein antigen.